Preclinical data in AMD is scientifically supportive of the platform's mechanism but does not change the near-term clinical catalyst — the Phase 1/2 TNBC trial. Monitor for patient enrollment updates or IND amendments expanding into retinal indications.
Price Chart
Executive Summary
Telomir Pharmaceuticals announced the peer-reviewed publication of preclinical data showing its lead compound Telomir-Zn restored visual function and retinal structure in a zebrafish model of age-related macular degeneration (AMD). The study demonstrated reduced mitochondrial oxidative stress, dose-dependent increases in telomeric DNA content, and inhibition of iron-dependent epigenetic enzymes. The company's clinical focus remains on oncology (Phase 1/2 TNBC trial), but the findings expand the platform's potential relevance beyond cancer.
Key Facts
- Peer-reviewed publication in International Journal of Molecular Sciences (2026, 27(18), 8265) showing Telomir-Zn improved visual function and retinal structure in a zebrafish AMD model after 14 days of oral treatment
- Telomir-Zn reduced brain reactive oxygen species (mitochondrial oxidative stress surrogate) with higher dose restoring values toward wild-type baseline
- Telomir-Zn dose-dependently increased relative telomeric DNA content toward healthy profile and restored altered DNA methylation patterns at aging-associated CpG loci
- Biochemical assays showed potent inhibition of Fe²⁺-dependent Jumonji C histone demethylases (KDMs), strongest against KDM5B at IC50 of 63 nM
- Company's clinical development remains focused on oncology — Telomir-Zn advancing under FDA-cleared IND for Phase 1/2 trial in advanced/metastatic triple-negative breast cancer (TNBC)
Financial Impact
No financial data in filing; preclinical publication with no revenue, guidance, or deal terms disclosed
Risk Factors
- Preclinical zebrafish data may not translate to human clinical outcomes in AMD
- Company remains pre-revenue with no disclosed financial runway or financing details in this filing
- Clinical focus on oncology means AMD development, if pursued, would require additional resources and regulatory pathway
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-043053 |
| Exhibit: ex99-1.htm | 0001493152-26-043053 |
| Document: 0001493152-26-043053-index-headers.html | 0001493152-26-043053 |
| Document: 0001493152-26-043053-index.html | 0001493152-26-043053 |
| Document: 0001493152-26-043053.txt | 0001493152-26-043053 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | 8-K | $1.20 | awaiting T+20 | — | $0.9990 (−16.75%) |
Sep 17, 2026 5w ago | 8-K | $1.12 $1.05 | ▼ −6.25% | ▼ −7.46% | $0.9990 (−10.80%) |
Sep 17, 2026 5w ago | Press Release | $1.12 $1.05 | ▼ −6.25% | ▼ −7.71% | $0.9990 (−10.80%) |
Sep 14, 2026 6w ago | 8-K | $1.17 $1.10 | ▼ −5.98% | ▼ −8.25% | $0.9990 (−14.62%) |
Aug 19, 2026 9w ago | DEFA14A | $1.17 $1.12 | ▼ −4.27% | ▼ −2.32% | $0.9990 (−14.62%) |
Aug 10, 2026 11w ago | 8-K | $1.17 $1.19 | ▲ +1.71% | ▲ +2.62% | $0.9990 (−14.62%) |
Jun 15, 2026 19w ago | 8-K | $1.29 $1.24 | ▼ −3.88% | ▼ −3.13% | $0.9990 (−22.56%) |
Jun 8, 2026 20w ago | 8-K | $1.21 $1.24 | ▲ +2.48% | ▲ +1.03% | $0.9990 (−17.44%) |
Apr 24, 2026 26w ago | 8-K | $1.40 $1.30 | ▼ −7.14% | ▼ −11.17% | $0.9990 (−28.64%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers